Drug safety alert: Canagliflozin (Invokana, Invokamet) may increase the risk of leg and foot amputations

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

ISSUE: Based on new data from two large clinical trials, the FDA has concluded that the type 2 diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. FDA is requiring new warnings, including the most prominent Boxed Warning, to be added to the canagliflozin drug labels to describe this risk.

Final results from two clinical trials – the CANVAS (Canagliflozin Cardiovascular Assessment Study) and CANVAS-R (A Study of the Effects of Canagliflozin on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus) – showed that leg and foot amputations occurred about twice as often in patients treated with canagliflozin compared to patients treated with placebo, which is an inactive treatment. Amputations of the toe and middle of the foot were the most common; however, amputations involving the leg, below and above the knee, also occurred. Some patients had more than one amputation, some involving both limbs. See the FDA Drug Safety Communication for additional information, including a data summary.

BACKGROUND: This information is an update to the May 18, 2016 MedWatch safety alert. Canagliflozin is a prescription medicine used with diet and exercise to lower blood sugar in adults with type 2 diabetes. It belongs to a class of drugs called sodium-glucose cotransporter-2 (SGLT2) inhibitors. Canagliflozin lowers blood sugar by causing the kidneys to remove sugar from the body through the urine. It is available as a single-ingredient product under the brand name Invokana and also in combination with...

Recommended for you

  • FDA Drug Updates
  • 1 comment

FDA approved Haegarda (C1 esterase inhibitor) for Hereditary Angioedema

Read more
  • MedWatch Drug Updates
  • 1 comment

Field Correction of system CS100, CS100i and CS300 Intra-Aortic Balloon Pumps by Datascope

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Clindamycin Injection USP ADD-Vantage vials by Alvogen: Presence of microbial growth

Read more
  • MedWatch Drug Updates
  • no comment

Recall of Nitroglycerin Injection in 5% Dextrose USP by Advanced Pharma due to sub-potency

Read more
  • MedWatch Drug Updates
  • no comment

Recall of Paliperidone Extended-Release tablets, 3mg by Teva Pharmaceuticals due to failure of dissolution test

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA safety alert: Navigational accuracy errors associated with frameless stereotaxic navigation systems

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of one lot Eliquis 5 mg tablets by Bristol-Myers Squibb- Contain product of incorrect strength

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of topical products by Phillips Company- Improper manufacturing practices affecting product's quality

Read more
  • MedWatch Drug Updates
  • no comment

Recall of Potassium Phosphate and Succinylcholine Chloride by Advanced Pharma - Presence of microbial growth

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Venture catheters by Vascular Solutions- Catheter tip may split or separate during use

Read more
  • MedWatch Drug Updates
  • 1 comment

Drug safety alert: Canagliflozin (Invokana, Invokamet) may increase the risk of leg and foot amputations

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Radicava (edaravone) for amyotrophic lateral sclerosis

Read more
  • MedWatch Drug Updates
  • 1 comment

Use of Medtronic’s NavLock Tracker with non-Medtronic instruments can cause spinal injury or death

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Rydapt (midostaurin) for acute myeloid leukemia

Read more
  • FDA Drug Updates
  • 1 comment

FDA expands approved use of Stivarga (regorafinib) for liver cancer

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Brineura (cerliponase alfa) for Batten disease

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of 25% Dextrose Injection, USP, (Infant) by Hospira- Presence of particulate matter

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of SpF PLUS-Mini and SpF XL IIb Implantable Spinal Fusion Stimulators by Zimmer Biomet

Read more
  • MedWatch Drug Updates
  • no comment

Recall of Mibela 24 Fe chewable tablet by Lupin Pharmaceuticals Inc- Packaging error affecting dosing regimen

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Ingrezza (valbenazine) for tardive dyskinesia

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of physician sample of Brilinta (ticagrelor) 90mg by AstraZeneca- Presence of another medicine Zurampic

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Ocrevus (ocrelizumab) for multiple sclerosis

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Zejula (niraparib) for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer

Read more
  • FDA Drug Updates
  • 1 comment

FDA approves Dupixent (dupilumab) for atopic dermatitis

Read more
  • MedWatch Drug Updates
  • 1 comment

Class I Recall of HeartMate II LVAS Pocket System Controller by Abbott-Thoratec- Controller malfunction after exchange

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Tri-Ton by Dynamic Technical Formulations LLC- Presence of unapproved drug andarine and ostarine

Read more
  • MedWatch Drug Updates
  • 1 comment

Gadolinium-based contrast agent for MRI- No adverse effects reported with gadolinium retention in the brain

Read more
  • MedWatch Drug Updates
  • 1 comment

Class I Recall of V60 Non-invasive ventilator by Respironics- Unexpected stop in ventilation therapy

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Bavencio (avelumab) for Merkel cell carcinoma

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Xadago (safinamide) for Parkinson’s disease

Read more